Paget disease: When to treat and when not to treat

Nature Reviews Rheumatology

Volumn 5, Issue 9, 2009, Pages 483-489

  Singer, Frederick R ^a  

^a SAINT JOHN'S HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT;

BONE DEVELOPMENT; DRUG EFFECT; HUMAN; INCIDENTAL FINDING; OSTEOCLAST; OSTEOLYSIS; PAGET BONE DISEASE; PAIN; REVIEW;

BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; HUMANS; INCIDENTAL FINDINGS; OSTEITIS DEFORMANS; OSTEOCLASTS; OSTEOGENESIS; OSTEOLYSIS; PAIN;

EID: 70350519843     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2009.149     Document Type: Review

References (71)

1. Paget, J. On a form of chronic inflammation of bones (osteitis deformans). Medico-Chirurgical Transactions of London 60, 37-63 (1877).
2. Maldague, B. & Malghem, J. Dynamic radiologic patterns of Paget's disease of bone. Clin. Orthop. Relat. Res. 217, 126-151 (1987).
3. Haddaway, M. J., Davie, M. W., McCall, I. W. & Howdle, S. Effect of age and gender on the number and distribution of sites in Paget's disease of bone. Br. J. Radiol. 80, 532-536 (2007).
4. Franck, W. A., Bress, N. M., Singer, F. R. & Krane, S. M. Rheumatic manifestations of Paget's disease of bone. Am. J. Med. 56, 592-603 (1974).
5. Shankar, S. & Hosking, D. J. Biochemical assessment of Paget's disease of bone. J. Bone Miner. Res. 21 (Suppl. 2), P22-P27 (2006).
6. Renier, J. C. & Audran, M. Progression in length and width of pagetic lesions, and estimation of age at disease onset. Rev. Rhum. Engl. Ed. 64, 35-43 (1997).
7. Daroszewska, A. & Ralston, S. H. Mechanisms of disease: genetics of Paget's disease of bone and related disorders. Nat. Clin. Pract. Rheumatol. 2, 270-277 (2006).
8. Wermers, R. A., Tiegs, R. D., Atkinson, E. J., Achenbach, S. J. & Melton, L. J. 3rd. Morbidity and mortality associated with Paget's disease of bone: a population-based study. J. Bone Miner. Res. 23, 819-825 (2008).
9. Mackenzie, I., Young, C. & Fraser, W. D. Tinnitus and Paget's disease of bone. J. Laryngol. Otol. 120, 899-902 (2006).
10. Smith, B. J. & Eveson, J. W. Paget's disease of bone with particular reference to dentistry. J. Oral Pathol. 10, 233-247 (1981).
11. Hadjipavlou, A. G., Gaitanis, L. N., Katonis, P G. & Lander, P. Paget's disease of the spine and its management. Eur. Spine J. 10, 370-384 (2001).
12. Dove, J. Complete fractures of the femur in Paget's disease of bone. J. Bone Joint Surg. Br. 62-13, 12-17 (1980).
13. Allen, M. L. & John, R. L. Osteitis deformans (Paget's disease). Fissure fractures—their etiology and clinical significance. Am. J. Roentgenol. Rad. Ther. 38, 109-115 (1937).
14. Marr, D. S., Rosenthal, D. I., Cohen, G. L. & Tomford, W. W. Rapid postoperative osteolysis in Paget disease. A case report. J. Bone Joint Surg. Am. 76, 274-277 (1994).
15. Deyrup, A. T. et al. Sarcomas arising in Paget disease of bone: a clinicopathologic analysis of 70 cases. Arch. Pathol. Lab. Med. 131, 942-946 (2007).
16. Mangham, D. C., Davie, M. W. & Grimer, R. J. Sarcoma arising in Paget's disease of bone: declining incidence and increasing age at presentation. Bone 44, 431-436 (2009).
17. Singer, F. R. & Mills, B. G. Giant cell tumor arising in Paget's disease of bone. Recurrences after 36 years. Clin. Orthop. Relat. Res. 293, 293-301 (1993).
18. Haworth S. Cardiac output in osteitis deformans. Clin. Sci. 12, 271-275 (1953).
19. Laroche, M. & Delmotte, A. Increased arterial calcification in Paget's disease of bone. Calcif. Tissue Int. 77, 129-133 (2005).
20. Strickberger, S. A., Schulman, S. P. & Hutchins, G. M. Association of Paget's disease of bone with calcific aortic valve disease. Am. J. Med. 82, 953-956 (1987).
21. Harrison, C. V. & Lennox, B. Heart block in osteitis deformans. Br. Heart J. 10, 167-176 (1948).
22. Reifenstein, E. C. Jr & Albright, F. Paget's disease: its pathologic physiology and the importance of the complications arising from fracture and immobilization. N. Engl. J. Med. 231, 343-355 (1944).
23. Gutteridge, D. H., Gruber, H. E., Kermode, D. G. & Worth, G. K. Thirty cases of concurrent Paget's disease and primary hyperparathyroidism: sex distribution, histomorphometry, and prediction of the skeletal response to parathyroidectomy. Calcif. Tissue Int. 65, 427-435 (1999).
24. Nagant de Deuxchaisnes, C. N. & Krane, S. M. Paget's disease of bone: clinical and metabolic observations. Medicine (Baltimore) 43, 233-266 (1964).
25. Singer, F. R. & Krane, S. M. in Metabolic Bone Disease (Eds Avioli, L. V. & Krane, S. M.) 552-553 (Academic Press, New York, 1978).
26. Ryan, W. G., Schwartz, T. B. & Perlia, C. P. Effects of mithramycin on Paget's disease of bone. Ann. Intern. Med. 70, 549-557 (1969).
27. Bockman, R. S. et al. A multicenter trial of low dose gallium nitrate in patients with advanced Paget's disease of bone. J. Clin. Endocrinol. Metab. 80, 595-602 (1995).
28. Sturtridge, W. C., Harrison, J. E. & Wilson, D. R. Long-term treatment of Paget's disease of bone with salmon calcitonin. Can. Med. Assoc. J. 117, 1031-1034 (1977).
29. el Sammaa, M., Linthicum, F. H. Jr. House, H. P. & House, J. W. Calcitonin as treatment for hearing loss in Paget's disease. Am. J. Otol. 7, 241-243 (1986).
30. Singer, F. R., Fredericks, R. S. & Minkin, C. Salmon calcitonin therapy for Paget's disease of bone. The problem of acquired clinical resistance. Arthritis Rheum. 23, 1148-1154 (1980).
31. Singer, F. R. Human calcitonin treatment of Paget's disease of bone. Clin. Orthop. Relat. Res. 127, 86-93 (1977).
32. Khairi, M. R. et al. Sodium etidronate in the treatment of Paget's disease of bone. A study of long-term results. Ann. Intern. Med. 87, 656-663 (1977).
33. Nancollas, G. H. et al. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone 38, 617-627 (2006).
34. Russell, R. G. Bisphosphonates: from bench to bedside. Ann. N. Y. Acad. Sci. 1068, 367-401 (2006).
35. Delmas, P D., Chapuy, M. C., Edouard, C. & Meunier, P J. Beneficial effects of aminohexane diphosphonate in patients with Paget's disease of bone resistant to sodium etidronate. Am. J. Med. 83, 276-282 (1987).
36. Evans, R. A., Dunstan, C. R., Hills, E. & Wong, S. Y. Pathologic fracture due to severe osteomalacia following low-dose diphosphonate treatment of Paget's disease of bone. Aust. N. Z. J. Med. 13, 277-279 (1983).
37. Altman, R. D. Long-term follow-up of therapy with intermittent etidronate disodium in Paget's disease of bone. Am. J. Med. 79, 583-590 (1985).
38. Stone, M. D., Hawthorne, A. B., Kerr, D., Webster, G. & Hosking, D. J. Treatment of Paget's disease with intermittent low-dose infusions of disodium pamidronate (APD). J. Bone Miner. Res. 5, 1231-1235 (1990).
39. Thiebaud, D., Jaeger, P., Gobelet, C., Jacquet, A. F. & Burckhardt, P. A single infusion of the bisphosphonate AHPrBP (APD) as treatment of Paget's disease of bone. Am. J. Med. 85, 207-212 (1988).
40. Cundy, T., Wattie, D. & King, A. R. High-dose pamidronate in the management of resistant Paget's disease. Calcif. Tissue Int. 58, 6-8 (1996).
41. Gutteridge, D. H. et al. Paget's disease: acquired resistance to one aminobisphosphonate with retained response to another. J. Bone Miner. Res. 14 (Suppl. 2), 79-84 (1999).
42. Siris, E. et al. Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone. J. Clin. Endocrinol. Metab. 81, 961-967 (1996).
43. de Groen, P C. et al. Esophagitis associated with the use of alendronate. N. Engl. J. Med. 335, 1016-1021 (1996).
44. Siris, E. S. et al. Risedronate in the treatment of Paget's disease of bone: an open label, multicenter study. J. Bone Miner. Res. 13, 1032-1038 (1998).
45. Reid, I. R. et al. Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. N. Engl. J. Med. 353, 898-908 (2005).
46. Hosking, D. et al. Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate. J. Bone Miner. Res. 22, 142-148 (2007).
47. Tziomalos, K. et al. Persistent effect of zoledronic acid in Paget's disease. Clin. Exp. Rheumatol. 25, 464-466 (2007).
48. Fraunfelder, F. W., Fraunfelder, F. T. & Jensvold, B. Scleritis and other ocular side effects associated with pamidronate disodium. Am. J. Ophthalmol. 135, 219-222 (2003).
49. Perazella, M. A. & Markowitz, G. S. Bisphosphonate nephrotoxicity. Kidney Int. 74, 1385-1393 (2008).
50. Shane, E. et al. Osteonecrosis of the jaw: more research needed. J. Bone Miner. Res. 21, 1503-1505 (2006).
51. Roohi, F., Mann, D. & Kula, R. W. Surgical management of hydrocephalic dementia in Paget's disease of bone: the 6-year outcome of ventriculo-peritoneal shunting. Clin. Neurol. Neurosurg. 107, 325-328 (2005).
52. McDonald, D. J. & Sim, F. H. Total hip arthroplasty in Paget's disease. A follow-up note. J. Bone Joint Surg. Am. 69, 766-772 (1987).
53. Lusty, P J., Walter, W. L., Walter, W. K. & Zicat, B. Cementless hip arthroplasty in Paget's disease at medium-term follow-up (average of 6.7 years). J. Arthroplasty 22, 692-696 (2007).
54. Gabel, G. T., Rand, J. A. & Sim, F. H. Total knee arthroplasty for osteoarthrosis in patients who have Paget disease of bone at the knee. J. Bone Joint Surg. Am. 73, 739-744 (1991).
55. Lee, G. C., Sanchez-Sotelo, J. & Berry, D. J. Total knee arthroplasty in patients with Paget's disease of bone at the knee. J. Arthroplasty 20, 689-693 (2005).
56. Meyers, M. H. & Singer, F. R. Osteotomy for tibia vara in Paget's disease under cover of calcitonin. J. Bone Joint Surg. Am. 60, 810-814 (1978).
57. Parvizi, J., Frankle, M. A., Tiegs, R. D. & Sim, F. H. Corrective osteotomy for deformity in Paget disease. J. Bone Joint Surg. Am. 85-A, 697-702 (2003).
58. Shardlow, D. L., Giannoudis, P V., Matthews, S. J. & Smith, R. M. Stabilisation of acute femoral fractures in Paget's disease. Int. Orthop. 23, 283-285 (1999).
59. Wootton, R., Reeve, J., Spellacy, E. & Tellez-Yudilevich, M. Skeletal blood flow in Paget's disease of bone and its response to calcitonin therapy. Clin. Sci. Mol. Med. 54, 69-74 (1978).
60. Eekhoff, M. E. et al. Paget's disease of bone in The Netherlands: a population-based radiological and biochemical survey-the Rotterdam Study. J. Bone Miner. Res. 19, 566-570 (2004).
61. Takata, S. et al. Guidelines for diagnosis and management of Paget's disease of bone in Japan. J. Bone Miner. Metab. 24, 359-367 (2006).
62. Selby, P L. Guidelines for the diagnosis and management of Paget's disease: a UK perspective. J. Bone Miner. Res. 21 (Suppl. 2), P92-P93 (2006).
63. Siris, E. S., Lyles, K. W., Singer, F. R. & Meunier, P J. Medical management of Paget's disease of bone: indications for treatment and review of current therapies. J. Bone Miner. Res. 21 (Suppl. 2), P94-P98 (2006).
64. Josse, R. G. et al. Diagnosis and treatment of Paget's disease of bone. Clin. Invest. Med. 30, E210-223 (2007).
65. Adami, S. et al. Italian guidelines for the diagnosis and treatment of Paget's disease of bone [Italian]. Reumatismo 59, 153-168 (2007).
66. Devogelaer, J. P et al. Management of patients with Paget's disease: a consensus document of the Belgian Bone Club. Osteoporos. Int. 19, 1109-1117 (2008).
67. Ralston, S. H. et al. Initial results from the PRISM study: a large randomized comparative trial of intensive versus symptomatic treatment for Paget's disease. J. Bone Miner. Res. 21 (Suppl. 1), LB1 (2006).
68. Nathan, A. W., Ludlam, H. A., Wilson, D. W. & Dandona, P. Hypercalcaemia due to immobilization of a patient with Paget's disease of bone. Postgrad. Med. J. 58, 714-715 (1982).
69. Meunier, P J. & Vignot, E. Therapeutic strategy in Paget's disease of bone. Bone 17, S489-S491 (1995).
70. Whitson, H. E., Lobaugh, B. & Lyles, K. W. Severe hypocalcemia following bisphosphonate treatment in a patient with Paget's disease of bone. Bone 39, 954-958 (2006).
71. Boyce, B. F. & Xing, L. Functions of RANKL/ RANK/OPG in bone modeling and remodeling. Arch. Biochem. Biophys. 473, 139-146 (2008).